---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009871"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:55:58.109269+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine reports $791M cash; bitopertin NDA under priority review with CNPV

## Summary
- Preliminary unaudited cash, equivalents and securities ~$791M as of Dec 31, 2025; runway into 2029.
- Bitopertin NDA for EPP accepted under accelerated approval; CNPV expected to accelerate FDA review to 1-2 months.
- Key 2026 milestones: updated Phase 2 data for DISC-0974 (MF anemia) and DISC-3405 (PV/SCD) in H2.
- Preparation for US launch of bitopertin if approved; commercial team and infrastructure build-out completed.
- Phase 2 study of DISC-0974 in anemia and inflammatory bowel disease to be initiated in 2026.

## SEC filing metadata
- accession: 0001193125-26-009871
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312526009871/0001193125-26-009871-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312526009871/iron-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009871
- JSON: https://secwatch.observer/filing/0001193125-26-009871.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009871.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.